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Abstract
BACKGROUND—To the authors’ knowledge, few studies to date have examined racial
differences in prostate cancer survival while controlling for socioeconomic status (SES). No such
studies have examined this association in Texas, a large state with significant ethnic and racial
diversity. The objective of this analysis was to determine whether racial disparities in survival for
men diagnosed with prostate cancer in Texas from 1995 through 2002 remained after adjusting for
SES, rural residence, and stage of disease.
METHODS—A cohort of 87,449 men who were diagnosed with prostate cancer was identified
from the Texas Cancer Registry. The SES measure was based on census tract data reflecting
median household income, median home value, and percentages of men living below poverty,
with a college education, and with a management or professional occupation. The 5-year survival
rates were calculated using the Kaplan-Meier method and Cox proportional hazard modeling was
used to estimate hazard ratios (HRs) for race and all-cause and disease-specific mortality.
RESULTS—After adjusting for SES, age, stage of disease, tumor grade, year of diagnosis, and
rural residence, both black and Hispanic men were more likely (adjusted HR [aHR], 1.70 [95%
confidence interval (95% CI), 1.58–1.83] and aHR, 1.11 [95% CI, 1.02–1.20], respectively) to die
of prostate cancer compared with white men. The pattern of survival disadvantage for black men
held for those diagnosed with localized disease and advanced disease, and for those with an
unknown stage of disease at diagnosis.
CONCLUSIONS—Substantial racial disparities in prostate cancer survival were found for men
in Texas. Future studies should incorporate treatment data as well as comorbid conditions because
this information may explain noted survival disparities.
INTRODUCTION
Prostate cancer is the most frequently diagnosed cancer in men in the United States.1 It is
estimated that 192,280 new cases and 27,360 deaths will have occurred from prostate cancer
in 2009.1 Despite the medical advances in detection and treatment, the burden of mortality
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varies by race/ethnicity. For the years 2000 to 2004, the age-adjusted mortality was much
higher for non-Hispanic black men than for non-Hispanic white men (59.4 per 100,000 vs.
24.6 per 10,000).1 Hispanics, American Indian/Alaskan Natives, and Asian American and
Pacific Islanders all had mortality rates lower than these 2 groups (20.6 per 100,000, 21.1
per 100,000, and 11.0 per 100,000, respectively).1
Racial/ethnic disparities in prostate cancer survival have also been documented in the
literature,2–12 and can be attributed to differences in socioeconomic status (SES),2,13–16
tumor stage at diagnosis,17,18 physician characteristics,19 rural residence,20 and treatment.
18–25 For studies that examined prostate cancer survival disparities by race/ethnicity and
incorporated SES,2,3,5,7,8,28 conflicting results regarding the role of SES in explaining
survival disparities were found. These inconsistencies are likely due to the utilization of
different proxy measures of SES, as well as not accounting for differences in stage of
disease at diagnosis, tumor characteristics, treatment, and other prognostic factors.
The majority of studies3,5,6,8–11,26–30 have explored the relation between race/ethnicity and
survival by comparing non-Hispanic black and non-Hispanic white men. To the best of our
knowledge, few studies to date have examined disparities among other racial/ethnic groups.
2,4,5,7,12 Only 1 study examined outcomes for Hispanic men and incorporated SES in
association with race/ethnicity to determine their role in prostate cancer survival, in addition
to factors such as cancer stage, tumor grade, comorbidities, and treatment.2 Furthermore, 2
studies examined the role of both race/ethnicity and SES in survival and included Asian
Americans in their analysis.5,7 One of these studies7 incorporated prognostic factors such as
treatment, tumor grade, and stage of disease at diagnosis. To the best of our knowledge, no
study has been reported for men with prostate cancer residing in Texas.
Therefore, this study aimed to assess disparities in survival among an ethnically diverse
group of men with prostate cancer who resided in Texas. The large population and racial/
ethnic diversity provides an optimal setting in which to study what factors (including SES)
explain racial disparities in prostate cancer survival and also to study several ethnic groups
of all ages that were under-represented in the literature. Although a previous study,2 which
used the Surveillance, Epidemiology, and End Results Program (SEER)-Medicare linked
database and incorporated racial/ethnicity, SES, and prognostic factors, found that
differences between racial/ethnic groups are because of SES, it is unclear whether these
differences are similar in men aged <65 years and at the state level in Texas, which is not
part of the SEER program. We hypothesized that compared with non-Hispanic white men,
non-Hispanic black men and Hispanic men would have poorer survival and Asian
American/Pacific Islander men would have better survival after controlling for differences in
patient demographics, neighborhood SES, tumor characteristics, rural residence, and year of
diagnosis.
MATERIALS AND METHODS
Data Sources
Incident prostate cancer cases were obtained from the Texas Cancer Registry, which is a
population-based database that collects data regarding cancers diagnosed in the state of
Texas. It has been annually awarded gold certification by the North American Association
of Central Cancer Registries since the submission of its 2003 cancer incidence data. Gold
certification indicates that the program has a case completeness rate >95%. The incident
prostate cancer cases, which were comprised of men aged ≥25 years who were diagnosed
with invasive primary prostate cancer (International Classification of Diseases for Oncology,
3rd edition [ICD-0-3] code C61.93) between January 1, 1995 and December 31, 2002, were
linked with the Texas Department of State Health Services mortality data through December
White et al. Page 2
Cancer. Author manuscript; available in PMC 2012 March 19.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
31, 2003 to obtain vital status. Death certificate information including date of death and
underlying cause of death was also acquired. The last date of follow-up was December 31,
2003. Institutional Review Boards from the Texas Department of State Health Services and
the University of Texas Health Science Center at Houston approved this study protocol.
Study Population
Race/ethnicity, which was defined by the race and Spanish/Hispanic origin variables
abstracted from medical records, was categorized as non-Hispanic white (referent group),
non-Hispanic black, Hispanic, and Asian/Pacific Islander.
The study population was comprised of 87,444 men diagnosed between January 1, 1995 and
December 31, 2002 with prostate cancer. All men were Texas residents aged ≥25 years. Of
these men, 74.9% (65,478) were non-Hispanic white (hereinafter referred to as white),
12.3% (10,770) were non-Hispanic black (hereinafter referred to as black), 12.2% (10,650)
were Hispanic, and 0.62% (546) were Asian/Pacific Islander (hereinafter referred to as
Asian).
Prostate Cancer Survival Definition
Survival time in days was calculated from the date of diagnosis to the date of death. For
cases that were missing the day of diagnosis, it was defined as the 15th of the month
(n=8753). For cases that only included the year of diagnosis but not the month or day, the
date of diagnosis was defined as June 15th (n=1571). Prostate cancer-specific mortality was
defined as death with prostate cancer as the underlying cause. Patients who died of causes
other than prostate cancer or were still alive at the time of last follow-up (December 31,
2003) were censored. All-cause mortality was defined as death from any underlying cause of
death. Underlying cause of death was defined by the Texas Department of State Health
Services Vital Statistics guidelines.
Socioeconomic Status
A census-derived composite variable was created to measure SES at the block group level.
All data were geocoded using Atlas (version 4.0; Lebanon, NH). The batch method was
initially used and any addresses that did not match were manually geocoded by relaxing
attributes such as ZIP code and street directionals. Although the majority of cases matched,
20% of cases did not and were randomly assigned to the block group of a randomly matched
case that was identical with regard to their ZIP code, race, age, and sex. The data were then
linked with census block group data to create an SES composite index.31 Measures included
in this index were the median household income, percentage of men living below poverty,
percentage with a college education, percentage with a management/professional
occupation, and median home value. These socioeconomic variables were first recoded to
ensure that lower values represented higher SES (median household income was made
negative). The values were then converted into normal scores. The 5 measures of SES were
then equally weighted, summed, and categorized using the quintile distribution for all men
with prostate cancer. Further information on creating this SES composite index is detailed
elsewhere.32
Patient and Tumor Characteristics
The following patient and tumor characteristics were also assessed in the study: year of
diagnosis (1995–2002), age (continuous), SEER summary tumor stage (localized, regional/
distant, or unknown), tumor grade (well differentiated, moderately differentiated, poorly
differentiated, undifferentiated, or unknown), and rural residence (urban, large town, small
town, or rural). Rural residence was defined using the Rural Urban Commuting Area Codes
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(RUCA), which uses Census Bureau urbanized area and urban cluster definitions in
combination with work commuting information to characterize census tracts regarding their
rural and urban status.33 The data were aggregated into the 4 categories mentioned above
using Categorization A.34
Statistical Analysis
All data were analyzed using the statistical software package Intercooled Stata (version 9.0;
StataCorp, College Station, TX). The distribution of baseline characteristics among the
racial/ethnic groups was assessed for differences using the chi-square statistic. The 5-year
survival was estimated using the Kaplan-Meier method. The log-rank test for equality of
survivor functions was used to determine whether there were differences in the observed
survival by race/ethnicity and SES. Cox proportional hazards regression models were used
to estimate the relative risk of dying of prostate cancer after adjusting for age, SES, tumor
stage, tumor grade, rural residence, and year of diagnosis. These models were also stratified
by tumor stage.
RESULTS
Table 1 presents the distribution of patient demographic and tumor characteristics for Asian,
Hispanic, black, and white men who were diagnosed with prostate cancer between 1995 and
2002. There were significant differences when comparing these groups. Black men were
diagnosed with prostate cancer an average age of 1 year earlier than white men. Black,
Asian, and Hispanic men were more likely to be diagnosed at a regional or distant stage
compared with white men, and black men were more likely to be have an unknown stage of
disease at diagnosis. Compared with white men, black and Asian men were less likely and
Hispanic men were more likely to have well-differentiated tumors. Furthermore, there were
statistically significant differences with regard to SES and rural residence when comparing
white men with Asian, black, and Hispanic men. Significantly higher percentages of black
(32.4%) and Hispanic men (34.1%) resided in very low socioeconomic areas compared with
7.9% of white men, whereas a greater percentage of Asian men (43.8%) resided in very high
socioeconomic areas compared with white men (35.5 %). Although the majority of all men
resided in urban areas, Hispanic and black men were less likely than white men to live in
rural areas of small towns.
Table 2 presents the unadjusted all-cause and prostate cancer-specific probability of
surviving ≥5 years by race/ethnicity and SES. Overall, survival was greatest for Asian men
and lowest for black men. The probability of surviving 5 years independent of the cause of
death was 79% for white men, 70% for black men, 74% for Hispanic men, and 86% for
Asian men. Prostate-specific survival probabilities followed a similar pattern by race: 92%
for white men, 83% for black men, 88% for Hispanic men, and 94% for Asian men. Those
who resided in neighborhoods of very low SES had poorer survival (70% all-cause survival)
compared with those who lived in areas with very high SES (83%). Similarly, prostate
cancer 5-year survival probabilities ranged from 85% for those residing in very low SES
areas to 94% for those residing in very high SES areas.
Table 3 compares the mortality associated with race/ethnicity in men diagnosed with
prostate cancer by stage at diagnosis during the years 1995 through 2002. After adjusting for
SES, age, tumor stage, tumor grade, rural residence, and year of diagnosis, black men were
more likely to die (adjusted hazard ratio [aHR], 1.36; 95% confidence interval [95% CI],
1.30–1.42) and Asian men were less likely to die (aHR, 0.65; 95% CI, 0.52–0.82) compared
with white men. For black men, the same trend was evident when their cancer was
diagnosed at either a local, regional/distant, or unknown stage (aHR, 1.28 [95% CI, 1.19–
1.36]; aHR, 1.49 [95% CI, 1.37–1.63]; and aHR, 1.35 [95% CI, 1.25–1.46], respectively.)
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Asian men were less likely than white men to die when their cancer was diagnosed at a local
stage (aHR, 0.49; 95% CI, 0.33–0.73).
With regard to overall prostate-specific mortality, compared with white men, black (aHR,
1.70; 95% CI, 1.58–1.83) and Hispanic men (aHR, 1.11; 95% CI, 1.02–1.20) were more
likely to die of prostate cancer (Table 4). Of those diagnosed at a local stage of disease,
black and Hispanic men were more likely to die compared with white men (aHR, 1.52 [95%
CI, 1.30–1.78] and aHR, 1.23 [95% CI, 1.05–1.44], respectively). Black men were also more
likely than white men to die when diagnosed at regional/distant and unknown stages (aHR,
1.70 [95% CI, 1.52–1.89] vs. aHR, 1.80 [95% CI, 1.57–2.05], respectively).
Table 5 shows predictors of prostate-specific mortality. Black men had a significantly higher
risk of dying (HR, 2.01; 95% CI, 1.89–2.17) compared with white men in the unadjusted
model. However, this risk was reduced after full adjustment for age, year of diagnosis,
tumor stage, tumor grade, SES, and urban/rural residence (HR, 1.70; 95% CI, 1.58–1.83).
For Hispanic men, the risk of death was higher than that for white men (HR, 1.55; 95% CI,
1.43–1.67) in the crude model. However, after full adjustment, their risk decreased but
remained higher than that of white men (HR, 1.11; 95% CI, 1.02–1.20).
Finally, to ensure similar follow-up time after diagnosis, we restricted the analysis to men
diagnosed between 1995 and 1998 and followed through 2003. The results for overall and
stage-specific all-cause mortality and prostate cancer-specific mortality were very similar to
the rates for men diagnosed from 1995 through 2002 (Table 3), and therefore are not
presented.
DISCUSSION
Although many studies have documented racial/ethnic disparities in prostate cancer survival,
2–12 to the best of our knowledge few have included Hispanic and Asian men in their
analyses and no study of this relation has been performed for men residing in Texas. Our
finding that black and Hispanic men in Texas have higher mortality whereas Asian men
have lower mortality from prostate cancer compared with white men is consistent with
studies that have explored race/ethnicity and mortality for these groups.2–11
Racial/ethnic disparities in survival have been attributed to many factors, including
differences in SES.2,7,8,26 A large proportion of black and Hispanic men resided in low SES
neighborhoods, and therefore controlling for SES was important for examining the relation
between ethnicity and survival. However, there may be residual confounding of SES
because we were not able to control for differences in SES at the individual level. The
results of the current study are consistent with studies that incorporated SES while
examining survival differences between race/ethnicity and found that the racial/ethnic
differences persisted after controlling for SES.3,5,8
The finding that black and Hispanic men have higher mortality from prostate cancer may be
explained by patient, provider, and health care system factors that influence treatment. A
mortality disadvantage was present at each stage of diagnosis for black men, even after
controlling for SES, tumor grade, and other factors. This disadvantage may be because of
differences in the receipt of treatment and access to high-quality healthcare. There is a
significant survival benefit in men who receive radical prostatectomy compared with those
treated with watchful waiting or radiotherapy.36 However, studies have documented that
black men are less likely than white men to receive definitive treatment8,37 and radical
prostatectomy,37–43 and are more likely to be treated with watchful waiting40 or not receive
treatment at all.38,39,44 Furthermore, Tewari et al found that lower prostate cancer survival
rates for African American men were explained by differences in SES and lower surgical
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treatment rates.45 In addition to differences in receipt of treatment, previous research has
shown that minority men are less likely to have access to high-quality healthcare. Bach et al
found that physicians treating black patients may be less well trained clinically and may
have limited access to clinical resources such as high-quality diagnostic imaging and high-
quality subspecialists than physicians treating white patients.19
Differences in tumor behavior may explain the disparities in prostate cancer mortality
observed in the current study. Previous research has shown that black men are at a greater
risk of developing prostate cancer and are more likely to have more aggressive tumors,17,18
which may explain an advanced stage of disease at the time of presentation and possibly
poorer subsequent survival. In this study, when compared with white men, black men were
slightly more likely to present with a regional/distant stage of disease and have poorly
differentiated tumors. Furthermore, the pattern of survival disadvantage for black men held
for those diagnosed with both localized disease and advanced disease, and those with an
unknown stage of disease at diagnosis. The risk of overall prostate cancer-specific mortality
was reduced significantly after adjusting for socio-demographic factors, tumor grade, and
stage, but black men still had poorer survival compared with white men.
There are several study strengths that support the validity of these findings. First, we were
able to examine survival in men aged ≥25 years and by race/ethnicity in traditionally
understudied groups: Hispanic and Asian men. These data and findings were unique because
to the best of our knowledge, no study to date has been conducted for men residing in Texas.
Furthermore, we used population-based data that met high national data quality standards,
including a cancer case completeness rate of >95%. Finally, using 8 years of data with 1-
year of follow-up yielded a large sample size (n= 87,449).
There were also a few limitations to the current study. First, there was limited information
regarding patient-level, provider-level, and system-level factors. Thus, we were unable to
incorporate the role that patient or physician treatment preferences, physician specialty, and
health insurance play in the disparities between these groups. Second, we had limited
clinical information and therefore were unable to account for differences in Gleason scores,
prostate-specific antigen (PSA) levels, treatment, and comorbid conditions, which are
reported to be associated with survival.18–25 However, in lieu of both Gleason scores and
PSA levels at diagnosis, we used tumor grade at the time of diagnosis as a measure of tumor
aggressiveness. Third, the sample size for Asian men was small and there may have been
limited power to test the hypothesis that they had better survival than white men.
Nevertheless, our finding that Asian men had better all-cause survival is consistent with
some previously published studies.5,7 Fourth, we did not have information regarding
individual-level SES. Rather, we used a composite variable for neighborhood SES and
therefore residual confounding may not have been adequately controlled for in our analyses.
In conclusion, substantial racial disparities in survival were found for men with prostate
cancer who resided in Texas. Black and Hispanic men were more likely to die of prostate
cancer and Asian men were less likely to die of all causes, even when adjusting for SES and
stage of disease and tumor grade at diagnosis compared with white men. This study
highlights the racial/ethnic disparities in prostate cancer survival in men residing in Texas.
Future research is needed to examine patient-level, provider-level, and system-level factors
that may that play a role in explaining the survival disparity.
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Table 3
Mortality associated with race/ethnicity in men with prostate carcinoma by SEER Summary stage at diagnosis,
1995–2002
Adjusted Hazard Ratio (95% CI) for Mortality
** Overall * Localized Stage * Regional/Distant Stage * Unknown Stage
Race/ethnicity
Non-Hispanic White 1.00 REF 1.00 REF 1.00 REF 1.00 REF
Non-Hispanic Black 1.36 (1.30–1.42) 1.28 (1.19–1.36) 1.49 (1.37–1.63) 1.35 (1.25–1.46)
Hispanic 0.96 (.92–1.00) 0.93 (0.87–1.00) 1.02 (0.93–1.12) 0.95 (0.88–1.03)
Asian/Pacific Islander 0.65 (0.52–0.82) 0.49 (0.33–0.73) 0.76 (0.51–1.14) 0.83 (0.56–1.24)
SES
Very high SES 1.00 REF 1.00 REF 1.00 REF 1.00 REF
High SES 1.16 (1.11–1.21) 1.14 (1.07–1.22) 1.26 (1.14–1.39) 1.11 (1.02–1.20)
Mid SES 1.22 (1.17–1.28) 1.28 (1.20–1.37) 1.19 (1.07–1.32) 1.16 (1.06–1.26)
Low SES 1.35 (1.28–1.41) 1.41 (1.31–1.51) 1.33 (1.20–1.48) 1.24 (1.13–1.35)
Very low SES 1.34 (1.28–1.41) 1.43 (1.33–1.54) 1.34 (1.20–1.49) 1.18 (1.08–1.30)
Age 1.083 (1.081–1.085) 1.095 (1.092–1.098) 1.067 (1.063–1.071 1.072 (1.069–1.076)
Tumor Grade
Well differentiated 1.00 REF 1.00 REF 1.00 REF 1.00 REF
Moderately differentiated 0.94 (.89–1.00) 0.98 (0.92–1.05) 0.98 (0.78–1.22) 1.00 (0.88–1.13)
Poorly differentiated 1.44 (1.35–1.53) 1.33 (1.23–1.44) 1.86 (1.49–2.32) 1.79 (1.58–2.04)
Undifferentiated 2.10 (1.86–2.39) 1.75 (1.40–2.19) 2.82 (2.16–3.69) 2.87 (2.24–3.68)
Unknown/Missing 1.65 (1.55–1.76) 1.15 (1.04–1.26) 3.20 (2.56–4.01) 1.83 (1.62–2.06)
Rural Residence
Urban 1.00 REF 1.00 REF 1.00 REF 1.00 REF
Large Town 1.02 (0.97–1.06) 1.02 (0.95–1.09) 1.07 (0.97–1.18) 1.00 (0.92–1.08)
Small Town 1.06 (0.99–1.13) 1.03 (0.94–1.14) 1.06 (0.92–1.21) 1.09 (0.98–1.20)
Rural 0.99 (0.92–1.10) 0.94 (0.81–1.09) 0.98 (0.80–1.21) 1.05 (0.90–1.23)
**
Adjusted for stage and year of diagnosis
*
Adjusted for year of diagnosis
#
Socioeconomic status (SES) is based on a census-derived composite index with quintiles ranging from very high to very low.
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Table 4
Prostate cancer-specific mortality associated with race/ethnicity in men with prostate carcinoma by SEER
Summary stage at diagnosis, 1995–2002
Adjusted Hazard Ratio (95% CI) for Mortality
** Overall * Localized Stage * Regional/Distant Stage * Unknown Stage
Race/ethnicity
Non-Hispanic White 1.00 REF 1.00 REF 1.00 REF 1.00 REF
Non-Hispanic Black 1.70 (1.58–1.83) 1.52 (1.30–1.78) 1.70 (1.52–1.89) 1.80 (1.57–2.05)
Hispanic 1.11 (1.02–1.20) 1.23 (1.05–1.44) 1.07 (.95–1.20) 1.07 (.93–1.24)
Asian/Pacific Islander 0.68 (.46–1.00) 0.42 (.13–1.30) 0.76 (.46–1.24) 0.74 (.35–1.56)
SES#
Very high SES 1.00 REF 1.00 REF 1.00 REF 1.00 REF
High SES 1.21 (1.12–1.32) 1.27 (1.07–1.51) 1.28 (1.13–1.45) 1.04 (.89–1.22)
Mid SES 1.20 (1.10–1.31) 1.34 (1.12–1.60) 1.17 (1.02–1.33) 1.14 (.97–1.33)
Low SES 1.44 (1.32–1.57) 1.90 (1.59–2.26) 1.26 (1.10–1.44) 1.31 (1.12–1.53)
Very low SES 1.36 (1.25–1.49) 1.70 (1.41–2.04) 1.34 (1.17–1.53) 1.14 (0.97–1.34)
Age 1.075 (1.072–1.079 1.107 (1.099–1.114) 1.065(1.061–1.069 1.065 (1.059–1.071
Tumor Grade
Well differentiated 1.00 REF 1.00 REF 1.00 REF 1.00 REF
Moderately differentiated 1.77 (1.44–2.16) 2.33 (1.72–3.16) 1.42 (.94–2.14) 1.49 (1.03–2.15)
Poorly differentiated 5.83 (4.77–7.12) 8.22 (6.08–11.12) 3.98 (2.65–5.96) 7.00 (4.88–10.03)
Undifferentiated 10.84 (8.54–13.77) 19.66 (13.08–29.55) 7.13 (4.60–11.04) 13.45 (8.45–21.48)
Unknown/Missing 6.85 (5.60–8.38) 4.59 (3.29–6.39) 7.24 (4.82–10.89) 6.38 (4.48–9.09)
Rural Residence
Urban 1.00 REF 1.00 REF 1.00 REF 1.00 REF
Large Town 1.04 (.96–1.13) 1.15 (.97–1.36) 1.11 (.98–1.26) 0.90 (.781–1.05)
Small Town 1.11 (.99–1.24) 1.14 (.90–1.45) 1.11 (.94–1.32) 1.07 (.88–1.30
Rural 0.95 (.79–1.14) 0.74 (.49–1.14) 0.93 (.712–1.22) 1.04 (0.78–1.40)
**
Also adjusted for stage and year of diagnosis
*
Also adjusted for year of diagnosis
#
Socioeconomic status (SES) is based on a census-derived composite index with quintiles ranging from very high to very low. composite index
with quintiles ranging from very high to very low.
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Table 5
Analysis of predictors of prostate cancer specific mortality for men diagnosed with prostate carcinoma, 1995–
2002
Model 1 *Model 2 *Model 3
Hazard Ratio (95% CI) Hazard Ratio (95% CI) Hazard Ratio (95% CI)
Race/ethnicity
Non-Hispanic White 1.00 REF 1.00 REF 1.00 REF
Non-Hispanic Black 2.01 (1.89–2.17) 1.84 (1.71–1.97) 1.70 (1.58–1.83)
Hispanic 1.55 (1.43–1.67) 1.20 (1.11–1.29) 1.11 (1.02–1.20)
Asian/Pacific Islander 0.88 (0.60–1.30) 0.79 (.54–1.16) 0.68 (.46–1.00)
Model 1 is unadjusted.
Model 2 adjusted for age (continuous), year of diagnosis, tumor stage and tumor grade, in addition to factors in Model 1.
Model 3 adjusted for socioeconomic status (based on census-derived composite index, in quintiles), rural residence, in addition to factors in Model
2.
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